DSTA 4637SAlternative Names: Anti-S. aureus TAC - Genentech; DSTA4637S; RG-7861
Latest Information Update: 10 Nov 2015
At a glance
- Originator Genentech
- Mechanism of Action Immunomodulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Staphylococcal infections
Most Recent Events
- 01 Oct 2015 Phase-I clinical trials in Staphylococcal infections (In volunteers) in USA (IV) (NCT02596399)